Powered by

-Blue Earth Diagnostics Announces Results of Investigational Phase 3 Blinded Image Evaluation Study of 18F-Fluciclovine PET Imaging in Glioma

Nov 20, 2018 - ENP Newswire

BURLINGTON - Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced results from an investigational Phase 3 blinded image evaluation (BIE) study of the diagnostic efficacy of 18F-fluciclovine positron emission tomography (PET) imaging, as an adjunct to magnetic resonance imaging (MRI), in adults with glioma.

The primary aim was to determine the diagnostic performance of 18F-fluciclovine PET when combined with MRI (CE-T1W MRI), compared to that of MRI (CE-T1W MRI) ...